Imperial College London
Alternate

Professor Francis Drobniewski

Faculty of Medicine, Department of Infectious Disease

Chair in Global Health and Tuberculosis
 
 
 
//

Contact

 

f.drobniewski

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Abubakar:2018:10.3310/hta22560,
author = {Abubakar, I and Lalvani, A and Southern, J and Sitch, A and Jackson, C and Onyimadu, O and Lipman, M and Deeks, JJ and Griffiths, C and Bothamley, G and Kon, OM and Hayward, A and Lord, J and Drobniewski, F},
doi = {10.3310/hta22560},
journal = {Health Technology Assessment},
pages = {1--95},
title = {Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study},
url = {http://dx.doi.org/10.3310/hta22560},
volume = {22},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Despite a recent decline in the annual incidence of tuberculosis (TB) in the UK, rates remain higher than in most Western European countries. The detection and treatment of latent TB infection (LTBI) is an essential component of the UK TB control programme. OBJECTIVES: To assess the prognostic value and cost-effectiveness of the current two interferon gamma release assays (IGRAs) compared with the standard tuberculin skin test (TST) for predicting active TB among untreated individuals at increased risk of TB: (1) contacts of active TB cases and (2) new entrants to the UK from high-TB-burden countries. DESIGN: A prospective cohort study and economic analysis. PARTICIPANTS AND SETTING: Participants were recruited in TB clinics, general practices and community settings. Contacts of active TB cases and migrants who were born in high-TB-burden countries arriving in the UK were eligible to take part if they were aged ≥ 16 years. MAIN OUTCOME MEASURES: Outcomes include incidence rate ratios comparing the incidence of active TB in those participants with a positive test result and those with a negative test result for each assay, and combination of tests and the cost per quality-adjusted life-year (QALY) for each screening strategy. RESULTS: A total of 10,045 participants were recruited between May 2010 and July 2015. Among 9610 evaluable participants, 97 (1.0%) developed active TB. For the primary analysis, all test data were available for 6380 participants, with 77 participants developing active TB. A positive result for TSTa (positive if induration is ≥ 5 mm) was a significantly poorer predictor of progression to active TB than a positive result for any of the other tests. Compared with TSTb [positive if induration is ≥ 6 mm without prior bacillus Calmette-Guérin (BCG) alone, T-SPOT®.TB (Oxford Immunotec Ltd, Oxford, UK), TSTa + T-SPOT.TB, TSTa + IGRA and the three combination
AU  - Abubakar,I
AU  - Lalvani,A
AU  - Southern,J
AU  - Sitch,A
AU  - Jackson,C
AU  - Onyimadu,O
AU  - Lipman,M
AU  - Deeks,JJ
AU  - Griffiths,C
AU  - Bothamley,G
AU  - Kon,OM
AU  - Hayward,A
AU  - Lord,J
AU  - Drobniewski,F
DO  - 10.3310/hta22560
EP  - 95
PY  - 2018///
SN  - 1366-5278
SP  - 1
TI  - Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study
T2  - Health Technology Assessment
UR  - http://dx.doi.org/10.3310/hta22560
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30334521
UR  - http://hdl.handle.net/10044/1/63841
VL  - 22
ER  -
Download